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Defining the activity of an enzyme in a cell-based sys-
tem is preferable to in vitro biochemical techniques
requiring extensive purification. Chiang et al. [1] use
small molecules, RNA interference, andmetabolomics
to characterize a novel enzyme upregulated in cancer
cells.
Traditional in vitro biochemistry is a powerful method for
the analysis of protein function. However, such experi-
ments often require purification and reconstitution steps
that are difficult and time consuming. Additionally, as
many proteins undergo posttranslational modifications
and/or are involved in large protein complexes, the re-
sults of in vitro assays may be difficult to translate to
in vivo systems. Cell-based methods avoid these prob-
lems as proteins are analyzed in a near-native system.
Examples of such techniques include the use of small
molecules, RNA interference (RNAi), and metabolic pro-
filing. In this issue of Chemistry & Biology, Chiang et al.
use these techniques to characterize the function and
substrate of an enzyme in a near-native cellular system
[1]. Chiang et al. and previous studies by Cravatt and
colleagues [2, 3, 4] also use a relatively new technique,
activity-based protein profiling (ABPP), in order to
annotate the function and substrate of a novel integral
membrane hydrolase, KIAA1363, upregulated in cancer
cells.
ABPP uses chemical probes directed against specific
enzyme families in order to profile altered enzyme activ-
ities in different contexts and to identify novel enzymes
[5, 6]. There are three parts to an ABPP probe: (1) a reac-
tive group that can covalently bind to the active site of an
enzyme family, (2) a linker region, and (3) a chemical tag
used to isolate the labeled enzymes [6]. Once cell ex-
tracts are treated with an ABPP probe, active enzymes
that have bound and reacted with the probe can be iden-
tified in a gel analysis. One major benefit of this tech-
nique is that ABPP measures enzyme activity, rather
than just monitoring protein abundance, which may or
may not represent activity. Additionally, enzymes are
monitored in cell extracts, avoiding the necessity for
protein purification and the development of enzyme-
substrate assays. Cell extracts are used, not whole cells,
as the probes are often too large to go though the cell
membrane. This can be overcome with tag-free probes
allowing for the use of intact cells [7]. Furthermore, in
an extension of the technique, termed competitive
ABPP, small molecules can be screened for inhibitory
activity against the ABPP probe, leading to identification
of potent and selective, cell-permeable inhibitors [4, 8].
Chiang et al. show that ABPP studies can lead to the
development of a potent and selective inhibitor for an
enzyme with an unknown function, normally a nearly
impossible task.Work leading to the current paper from the Cravatt
lab began when ABPP was used to screen for serine hy-
drolase activity in different cancer cell lines (Figure 1) [3].
In this experiment, a novel integral membrane hydro-
lase, KIAA1363, was found to be upregulated in cancer
cells. A previously identified fluorophosphonate ABPP
probe, which was known to interact with the hydrolase
family of enzymes [2], was used for competitive ABPP
studies. This led to the identification of a set of reversible
trifluoromethyl ketone (TFMK) inhibitors against the
mouse ortholog of KIAA1363 [4]. Although the TFMK in-
hibitors were not active against the human ortholog of
KIAA1363 in cells, these studies enabled Chiang et al.
to synthesize a TFMK analog, AS115 [1]. AS115 was
found to inhibit KIAA1363 with an IC50 of 150 nM in cells.
AS115 was subsequently used for cell-based studies of
KIAA1363 in order to determine the substrate of the en-
zyme and to uncover its role in the ether lipid signaling
pathway.
In traditional in vitro assays, identifying novel endoge-
nous substrates for an enzyme can be a daunting
challenge. The ‘‘discovery metabolite profiling’’ (DMP)
method overcomes this issue by using liquid chromatog-
raphy-mass spectrometry (LC-MS) to identify the sub-
strates of an enzyme by analyzing the metabolites of
cells in which the enzyme of interest is either active or in-
active [9]. A small-molecule inhibitor is used to inactivate
the enzyme; however, RNAi can theoretically be used if
an active small-molecule inhibitor is not known. The
main benefit of this technique is that it allows for the de-
termination of endogenous substrates within a cell. The
confounding problem is that secondary substrates may
be identified; however, this could turn into an advantage,
as these additional substrates may be helpful in defining
the pathway in which the enzyme is involved.
To identify substrates of KIAA1363, Chiang et al. pro-
filed cells with and without AS115, using LC-MS (Fig-
ure 1) [1]. They identified a difference in a set of lipophilic
metabolites and subsequently confirmed them to be
monoalkylglycerol ethers (MAGEs) by high resolution
MS. This suggested that MAGEs are products of
a KIAA1363-enzymatic reaction.
The biosynthesis of MAGE by the hydrolysis of 2-ace-
tyl MAGE in the ether lipid pathway has previous been
proposed [10, 11]. Chiang et al. were able to identify
KIAA1363 as a missing enzyme in this pathway, convert-
ing 2-acetyl MAGE to MAGE. The use of the inhibitor
AS115 and the comparison of cell lines varying in
KIAA1363 expression levels were essential to the identi-
fication of KIAA1363 in this pathway.
As KIAA1363 activity is elevated in invasive cancers
[3], Chiang et al. used RNAi to determine the effects of
KIAA1363 depletion on cancer cells. They found that
KIAA1363-knockdown cells had reduced tumor growth
and impaired in vitro migration, compared to controls.
Additionally, lower levels of MAGE and lysophospho-
lipids were found in KIAA1363-knockdown cells, corre-
lating with a decrease in KIAA1363 function. Thus,
KIAA1363 contributes to cancer invasiveness through
its regulation of the ether lipid metabolic pathway.
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The use of ABPP identified a novel enzyme, KIAA1363, upregulated in cancer cells, but not in normal cells. Competitive ABPP facilitated the de-
velopment of a small-molecule inhibitor of KIAA1363, AS115. Metabolic profiling was performed with AS115 to identify the endogenous substrate
of KIAA1363. Further small-molecule studies with AS115 allowed for the biochemical annotation of KIAA1363 in a near-native system.KIAA1363 is a model example displaying how ABPP
can be used to classify cancer cells with different pro-
teomic signatures. In these and many other cases, mon-
itoring enzymatic activity may be more valuable than just
monitoring protein expression levels. New protein tar-
gets for cancer therapeutics and new biomarkers for
cancer can be identified in this manner. KIAA1363 was
found to be upregulated in many cancers such as ovar-
ian [1], breast [3], melanoma [3], and pancreatic cancer
[12]. For KIAA1363, Chiang et al. were able to validate
its potential use as a therapeutic target and as a new
biomarker for cancer.
To date there are a limited number of ‘‘druggable tar-
gets’’ or proteins that can be selectively inhibited by
small molecules. Competitive ABPP is a valuable ap-
proach for finding small-molecule inhibitors of enzymes,
thereby increasing the number of druggable targets.
This is especially true for enzymes of unknown function,
as the specific function of the enzyme is typically neces-
sary for small-molecule screening, but not for competi-
tive ABPP studies. Expanding the use of small mole-
cules to a wider range of proteins will have benefits for
both basic research and disease treatment.
One final element of ABPP is the exciting prospect of
chemical probe libraries targeting novel classes of en-
zymes. Enzyme classes with mechanistically defined
active sites have enabled the development of ABPP
probes, such as for the serine hydrolase family [2] and
papain family of cysteine proteases [8]. However, the
majority of enzyme classes have no known small-
molecule scaffolds for the development of such probes.
Moving to remedy this deficit, Adam et al. describe non-
directed ABPP in which a specific library of reactive
group probes was tested in order to broaden the
ABPP technique to a wider group of enzymes [13]. To
extend this further to other classes of enzymes, a more
chemically and structurally diverse set of probe libraries
must be constructed [6].
Ultimately, the combination of ABPP and metabolic
profiling should allow for annotation of large numbersof enzymes with currently unknown functions. This
advance will have a major impact on target discovery,
target validation, and biomarker development.
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